TransThera Sciences (Nanjing) (HKSE:02617) Total Liabilities: HK$143.10 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02617 TransThera Sciences (Nanjing) Inc HKSE:02617
9 GF Score
Price HK$10.31
! 2 Warning Signs
View Full Analysis

What is TransThera Sciences (Nanjing) Total Liabilities?

TransThera Sciences (Nanjing) HKSE:02617 -0.67% 9 Total Liabilities is HK$143.10 Mil as of Dec. 2025. GuruFocus rates HKSE:02617 with a GF Score™ of 9/100. The stock has 2 warning signs investors should review.

TransThera Sciences (Nanjing)'s Total Liabilities for the quarter that ended in Dec. 2025 was HK$143.10 Mil.

TransThera Sciences (Nanjing)'s quarterly Total Liabilities increased from Dec. 2024 (HK$111.64 Mil) to Jun. 2025 (HK$120.96 Mil) and increased from Jun. 2025 (HK$120.96 Mil) to Dec. 2025 (HK$143.10 Mil).

TransThera Sciences (Nanjing)'s annual Total Liabilities declined from Dec. 2023 (HK$113.66 Mil) to Dec. 2024 (HK$111.64 Mil) but then increased from Dec. 2024 (HK$111.64 Mil) to Dec. 2025 (HK$143.10 Mil).

TransThera Sciences (Nanjing) Total Liabilities Historical Data

* Premium members only.

The historical data trend for TransThera Sciences (Nanjing)'s Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TransThera Sciences (Nanjing) Total Liabilities Chart

TransThera Sciences (Nanjing) Annual Data
Trend Dec23 Dec24 Dec25
Total Liabilities
113.66 111.64 143.10

TransThera Sciences (Nanjing) Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities 113.66 0.00 111.64 120.96 143.10
HKSE:02617
9GF Score
TransThera Sciences (Nanjing) Inc HKSE:02617
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TransThera Sciences (Nanjing) Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

TransThera Sciences (Nanjing)'s Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=143.096+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=143.10

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=603.077-459.981
=143.10

TransThera Sciences (Nanjing)'s Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=143.096+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=143.10

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=603.077-459.981
=143.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of HK$143.10 Mil mean?
TransThera Sciences (Nanjing) (HKSE:02617) has a Total Liabilities of HK$143.10 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for TransThera Sciences (Nanjing) and its competitors.
Is TransThera Sciences (Nanjing)'s Total Liabilities too high?
TransThera Sciences (Nanjing)'s current Total Liabilities is HK$143.10 Mil. Overall, TransThera Sciences (Nanjing) has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does TransThera Sciences (Nanjing)'s Total Liabilities compare to VRTX and REGN?
TransThera Sciences (Nanjing)'s Total Liabilities of HK$143.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for TransThera Sciences (Nanjing) and its competitors. TransThera Sciences (Nanjing)'s current Total Liabilities is HK$143.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransThera Sciences (Nanjing) stock overvalued right now?
TransThera Sciences (Nanjing) (HKSE:02617) has a current Total Liabilities of HK$143.10 Mil. The current Total Liabilities is HK$143.10 Mil. TransThera Sciences (Nanjing)'s overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For TransThera Sciences (Nanjing) (HKSE:02617), the current Total Liabilities is HK$143.10 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TransThera Sciences (Nanjing) Business Description

Other Exchanges J8J:Germany
Address Biotech and Pharmaceutical Valley, 3rd floor, Building 9, Accelerator Phase 2, Jiangbei New Area, Jiangsu Province, Nanjing, CHN, 210032
TransThera Sciences (Nanjing) Inc is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing inventive small molecule therapies for oncology, inflammatory and cardiometabolic diseases. It has internally discovered and developed one Core Product Tinengotinib (TT-00420) and built a pipeline of five clinical stage product candidates and one preclinical stage product candidate with its fully-integrated in-house R&D system. Its core Product Tinengotinib is a multi-targeted kinase (MTK) inhibitor targeting three key pathways. It is undergoing two pivotal/registrational clinical trials for the treatment of cholangiocarcinoma that has progressed following prior FGFR inhibitor therapy, one being conducted in China.
9GF Score

Get the complete analysis for HKSE:02617

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$10.31
Price